Saturday 17 October 2026
Export ARAV’s income statement to Excel — free account
ARAVIVE, INC
ARAV Healthcare Biotechnology
ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million. Revenue growth for five consecutive years.
Follow ARAV
| Older periods | Dec '22 | Mar '23 | Jun '23 | Sep '23 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 3 | 2 |
| (288.67%) | (38,510.54%) | (1,497.43%) | (475.98%) | ||
| (117.47%) | (193.68%) | (188.01%) | (144.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(211.25%) | (592.44%) | (955.85%) | 83,014.58% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.88) | (0.92) | (0.91) | (0.78) | |
Free Cash Flow |
(68.42) | (69.94) | (68.58) | (59.45) | |
Capital Expenditures |
(3.34) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(106.33%) | 2,602.94% | 4,703.43% | (580.81%) | |
Accounts Receivable Turnover |
7.06 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.20 | 0.13 | 0.20 | 0.12 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
2,856.45 | 4,034.77 | 1,616.55 | 2,249.31 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
732.60% | 732.50% | 688.70% | 763.23% | |
Selling, General and Administrative Expense of Revenue |
142.67% | 140.91% | 138.99% | 184.19% | |
Share Based Compensation of Revenue |
28.02% | 27.56% | 28.97% | 33.12% | |
Interest Coverage |
(108.48) | (66.44) | (47.83) | (40.57) | |
Operating CF/Net income |
0.85 | 0.62 | 0.89 | 1.49 | |
Depreciation/Fixed assets |
3.28 | 3.66 | 4.31 | 5.27 | |
Capex/Depreciation |
(3.77) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.25 | 0.13 | 0.12 | 0.09 | |
Operating CF per Share |
(1.79) | (0.92) | (0.91) | (0.78) | |
Capex per Share |
(0.09) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.37 | 0.00 | 0.00 | 0.00 |
Columns are period end dates